| Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial BL Andersen, HC Yang, WB Farrar, DM Golden‐Kreutz, CF Emery, ... Cancer 113 (12), 3450-3458, 2008 | 617 | 2008 |
| Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial BL Andersen, WB Farrar, DM Golden-Kreutz, R Glaser, CF Emery, ... Journal of clinical oncology: official journal of the American Society of …, 2004 | 585 | 2004 |
| Pain, depression, and fatigue: loneliness as a longitudinal risk factor. LM Jaremka, RR Andridge, CP Fagundes, CM Alfano, SP Povoski, ... Health Psychology 33 (9), 948, 2014 | 405 | 2014 |
| Myeloid derived suppressor cells–a new therapeutic target in the treatment of cancer R Wesolowski, J Markowitz, WE Carson Journal for immunotherapy of cancer 1, 1-11, 2013 | 349 | 2013 |
| Distress reduction from a psychological intervention contributes to improved health for cancer patients BL Andersen, WB Farrar, D Golden-Kreutz, CF Emery, R Glaser, ... Brain, behavior, and immunity 21 (7), 953-961, 2007 | 274 | 2007 |
| Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology D Shu, H Li, Y Shu, G Xiong, WE Carson III, F Haque, R Xu, P Guo ACS nano 9 (10), 9731-9740, 2015 | 267 | 2015 |
| Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice BL Mundy-Bosse, GB Lesinski, AC Jaime-Ramirez, K Benninger, M Khan, ... Cancer research 71 (15), 5101-5110, 2011 | 230 | 2011 |
| Social support predicts inflammation, pain, and depressive symptoms: longitudinal relationships among breast cancer survivors S Hughes, LM Jaremka, CM Alfano, R Glaser, SP Povoski, AM Lipari, ... Psychoneuroendocrinology 42, 38-44, 2014 | 229 | 2014 |
| Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer M Elbaz, MW Nasser, J Ravi, NA Wani, DK Ahirwar, H Zhao, S Oghumu, ... Molecular oncology 9 (4), 906-919, 2015 | 227 | 2015 |
| Signaling pathways involved in MDSC regulation P Trikha, WE Carson III Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (1), 55-65, 2014 | 221 | 2014 |
| BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma KB Kim, JA Sosman, JP Fruehauf, GP Linette, SN Markovic, ... Journal of Clinical Oncology 30 (1), 34, 2012 | 207 | 2012 |
| Myeloid-derived suppressor cells in breast cancer J Markowitz, R Wesolowski, T Papenfuss, TR Brooks, WE Carson Breast cancer research and treatment 140, 13-21, 2013 | 205 | 2013 |
| Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants BL Andersen, LM Thornton, CL Shapiro, WB Farrar, BL Mundy, HC Yang, ... Clinical Cancer Research 16 (12), 3270-3278, 2010 | 201 | 2010 |
| Natural killer cells produce T cell–recruiting chemokines in response to antibody-coated tumor cells JM Roda, R Parihar, C Magro, GJ Nuovo, S Tridandapani, WE Carson III Cancer research 66 (1), 517-526, 2006 | 201 | 2006 |
| A progenitor cell expressing transcription factor RORγt generates all human innate lymphoid cell subsets SD Scoville, BL Mundy-Bosse, MH Zhang, L Chen, X Zhang, KA Keller, ... Immunity 44 (5), 1140-1150, 2016 | 194 | 2016 |
| Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment A Stiff, P Trikha, R Wesolowski, K Kendra, V Hsu, S Uppati, E McMichael, ... Cancer research 76 (8), 2125-2136, 2016 | 190 | 2016 |
| Review of S100A9 biology and its role in cancer J Markowitz, WE Carson III Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1835 (1), 100-109, 2013 | 187 | 2013 |
| The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor–positive tumor cells is enhanced by cytokines JM Roda, T Joshi, JP Butchar, JW McAlees, A Lehman, S Tridandapani, ... Clinical Cancer Research 13 (21), 6419-6428, 2007 | 184 | 2007 |
| The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse GB Lesinski, M Anghelina, J Zimmerer, T Bakalakos, B Badgwell, ... The Journal of clinical investigation 112 (2), 170-180, 2003 | 173 | 2003 |
| Interleukin-21 enhances NK cell activation in response to antibody-coated targets JM Roda, R Parihar, A Lehman, A Mani, S Tridandapani, WE Carson The Journal of Immunology 177 (1), 120-129, 2006 | 154 | 2006 |
